Abbvie FY Revenues up 23%

Abbvie
4Q Revenues: $14.9 billion (+7%)
4Q Earnings: $4.0 billion (earnings were $36 million 4Q21)
FY Revenues: $56.2 billion (+23%)
FY Earnings: $3.4 billion (-10%)
Comments: Global Humira revenues were $5.3 billion in the quarter, an increase of 3.5%. Global Skyrizi revenues were $895 million and Rinvoq revenues were $517 million. Global revenues from the hematologic oncology portfolio were $1.9 billion, an increase of 4.6% in the quarter. Global Imbruvica revenues were $1.385 billion, a decrease of 2.7 percent, with U.S. net revenues of $1.114 billion and international profit sharing of $271 million. Global Venclexta revenues were $488 million, an increase of 33%. Global revenues from the neuroscience portfolio were $1.65 billion, an increase of 19%. Global Botox Therapeutic revenues were $671 million, an increase of 18%. Vraylar net revenues were $489 million, an increase of 22%. Global Ubrelvy net revenues were $183 million in the quarter.

In the quarter, AbbVie received FDA approval for Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment. This milestone marked the third FDA-approved indication for Rinvoq. The FDA also approved Rinvoq for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. The FDA approved Skyrizi for the treatment of adults with active PsA. This is the second FDA-approved indication for Skyrizi.